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Summary
Background Epidemiological studies have linked lifestyle, cardiometabolic, reproductive, developmental, and 
inflammatory factors to the risk of colorectal cancer. However, which specific factors affect risk and the strength of 
these effects are unknown. We aimed to examine the relationship between potentially modifiable risk factors and 
colorectal cancer.
Methods We used a random-effects model to examine the relationship between 39 potentially modifiable risk factors and 
colorectal cancer in 26 397 patients with colorectal cancer and 41 481 controls (ie, people without colorectal cancer). These 
population data came from a genome-wide association study of people of European ancestry, which was amended to 
exclude UK BioBank data. In the model, we used genetic variants as instruments via two-sample mendelian randomisation 
to limit bias from confounding and reverse causation. We calculated odds ratios per genetically predicted SD unit 
increase in each putative risk factor (ORSD) for colorectal cancer risk. We did mendelian randomisation Egger regressions 
to identify evidence of potential violations of mendelian randomisation assumptions. A Bonferroni-corrected threshold 
of p=1·3 × 10–³ was considered significant, and p values less than 0·05 were considered to be suggestive of an association.
Findings No putative risk factors were significantly associated with colorectal cancer risk after correction for multiple 
testing. However, suggestive associations with increased risk were noted for genetically predicted body fat percentage 
(ORSD 1·14 [95% CI 1·03–1·25]; p=0·0086), body-mass index (1·09 [1·01–1·17]; p=0·023), waist circumference 
(1·13 [1·02–1·26]; p=0·018), basal metabolic rate (1·10 [1·03–1·18]; p=0·0079), and concentrations of LDL cholesterol 
(1·14 [1·04–1·25]; p=0·0056), total cholesterol (1·09 [1·01–1·18]; p=0·025), circulating serum iron (1·17 [1·00–1·36]; 
p=0·049), and serum vitamin B12 (1·21 [1·04–1·42]; p=0·016), although potential pleiotropy among genetic variants 
used as instruments for vitamin B12 constrains the finding. A suggestive association was also noted between adult 
height and increased risk of colorectal cancer (ORSD 1·04 [95% CI 1·00–1·08]; p=0·032). Low blood selenium 
concentration had a suggestive association with decreased risk of colorectal cancer (ORSD 0·85 [95% CI 0·75–0·96]; 
p=0·0078) based on a single variant, as did plasma concentrations of interleukin-6 receptor subunit α (also based on 
a single variant; 0·98 [0·96–1·00]; p=0·035). Risk of colorectal cancer was not associated with any sex hormone or 
reproductive factor, serum calcium, or circulating 25-hydroxyvitamin D concentrations.
Interpretation This analysis identified several modifiable targets for primary prevention of colorectal cancer, including 
lifestyle, obesity, and cardiometabolic factors, that should inform public health policy.
Funding Cancer Research UK, UK Medical Research Council Human Genetics Unit Centre, DJ Fielding Medical 
Research Trust, EU COST Action, and the US National Cancer Institute.
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Introduction
Colorectal cancer is the third most commonly diagnosed 
cancer and the second leading cause of cancer-related 
death in the world.1 It accounted for around 1·8 million 
new cases and 860 000 deaths in 2018.1 According to 
demographic trajectories, the yearly global burden of 
colorectal cancer is projected to increase to more than 
3 million new cases and 1·6 million deaths by 2040.1 
Differences in the incidence of colorectal cancer between 
countries and studies of international migration have 
suggested a role for dietary and other lifestyle factors in 
disease development.2 Thus, interest is increasing in the 
development of public health programmes to reduce 
the incidence of colorectal cancer by targeting modifiable 
risk factors.
The World Cancer Research Fund and the American 
Institute for Cancer Research have concluded that there is 
convincing evidence that body-mass index (BMI) and 
alcohol intake are causally associated with increased risk of 
colorectal cancer, and that physical activity is causally 
associated with reduced risk.3 They also concluded that red 
meat intake is probably causally associated with increased 
risk, whereas dietary fibre, dairy products, and calcium 
supplements are probably causally associ ated with reduced 
risk.3 For most other risk factors, however, evidence is too 
inconclusive to reliably establish causal associations.3
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Much of the available evidence for causal relationships 
between potentially modifiable factors and risk of colo-
rectal cancer comes from observational studies,3 which 
are susceptible to confounding bias and reverse causa-
tion.4 Data from randomised trials tend to be scarce and 
are often inconclusive.5,6 Furthermore, identification of 
which specific components of risk factors such as diet 
are important is notoriously problematic in conventional 
observational epidemiological studies.7 Mendelian ran-
dom is a tion is an analytic approach in which germline 
genetic vari ants are used as proxies, or instrumental vari-
ables, for putative risk factors.8 Because these genetic 
variants are randomly assorted at conception, they are not 
influ enced by reverse causation, and, in the absence of 
pleiotropy (ie, associations between genetic variants and 
disease through alternative pathways), they can provide 
unconfounded estimates of disease risk.8 Mendelian 
randomisation analyses are increas ingly used to examine 
the potential effects of inter ventions on disease risk 
because they circumvent many of the limitations of 
conventional observational studies.
In this study, we investigated potentially causal and 
modifiable risk factors for colorectal cancer by using a 
two-sample mendelian randomisation framework, in 
which genetic variants associated with relevant risk 
factors as instrumental variables were first identified 
from genome-wide association studies (GWAS). We then 
assessed the association between these instrumental 
variables and colorectal cancer in a large GWAS.
Methods
Identification of risk factors
In this two-sample mendelian randomisation analysis, 
we used genetic variants as instruments to examine the 
relationship between 39 potentially modifiable risk 
factors and colorectal cancer. The genetic variant data 
were from patients with colorectal cancer and controls 
(ie, people without colorectal cancer) who were recruited 
to GWASs of people of European ancestry before May, 
2019.
We focused on potentially modifiable dietary, lifestyle, 
obesity-related, inflammatory, reproductive, and develop-
mental factors that were discussed in association with 
the risk of colorectal cancer in a report by the World 
Cancer Research Fund and the American Institute for 
Cancer Research.3 We also searched PubMed to identify 
additional modifiable risk factors for colorectal cancer 
that have been reviewed in published epidemiological 
meta-analyses (up to Nov 30, 2018) or mendelian 
randomisation analyses (up to March 1, 2019; appendix 1 
p 1; appendix 2 table S1). Ethical approval was not sought 
for this specific project because all data came from sum-
mary statistics of published GWAS, and no individual-
level data were used.
Single-nucleotide polymorphisms (SNPs) associated 
with putative risk factor traits suitable for use in 
mendelian randomisation analyses were identified from 
the largest GWAS or meta-analysis of each trait done to 
date (appendix 2 table S2). Traits were only considered if 
the proportion of variance explained by the associated 
SNPs was greater than 0·1%. Estimates of the proportion 
of variance explained were either obtained directly from 
publications or computed directly from the association 
statistics.9 Suitable genetic instruments were not avail-
able for many risk factors, such as physical activity, 
dietary patterns, and vitamin C intake, which precluded 
their inclusion (appendix 2 table S1). We considered only 
continuous traits, because analysis of binary traits 
(eg, disease status) with binary outcomes in two-sample 
mendelian randomisation frameworks can result in 
Research in context
Evidence before this study
We searched PubMed to identify dietary, lifestyle, 
obesity-related, inflammatory, reproductive, and developmental 
factors potentially affecting risk of colorectal cancer that had 
been assessed in observational epidemiological studies published 
in English up to Nov 30, 2018. Appendix 1 (p 1) includes a full list 
of search terms used. Studies provide strong evidence for an 
association between body-mass index and hypercholesterolaemia 
and increased risk of colorectal cancer. Evidence from 
conventional observational studies for most other factors is too 
inconclusive to reliably establish specific associations.
Added value of this study
Mendelian randomisation exploits germline genetic variants as 
instrumental variables for putative risk factors. Because these 
genetic variants are randomly assorted at conception, they are 
not affected by reverse causation and so can provide evidence 
for causal relationships. We used genetic variants for 
39 potentially modifiable risk factors in 26 397 patients with 
colorectal cancer and 41 481 controls who did not have 
colorectal cancer. We identified suggestive evidence for 
associations between serum vitamin B12, iron, and selenium 
concentrations and colorectal cancer. In addition to providing 
suggestive evidence for a causal relationship between high 
body-mass index and other measures of obesity and increased 
colorectal cancer risk, we found evidence for an association 
between genetically predicted LDL cholesterol and increased 
colorectal cancer risk.
Implications of all the available evidence
Our analysis provides genetic corroboration of causal 
relationships between raised body-mass index, 
hypercholesterolaemia, and increased colorectal cancer risk. 
Our findings support the restriction of vitamin B12 
supplementation to people with a known indication, such as 
proven deficiency, and highlight important targets for primary 
prevention of colorectal cancer, including lifestyle, obesity, and 
cardiometabolic factors.
See Online for appendix 2
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inaccurate causal estimates.10 Only SNPs associated with 
each trait at p values of less than 5 × 10–⁸ in a GWAS of 
European populations with a minor allele frequency 
greater than 0·01 were considered as potential instru-
ments. To mitigate against co-linearity between SNPs, 
which can bias causal effect estimates, we used MR-Base 
to exclude correlated SNPs at a linkage disequilibrium 
threshold of r² greater than 0·01, and retained SNPs with 
the strongest effect on the associated trait.11
Procedures
To examine the association of each genetic instrument 
with the risk of colorectal cancer, we used summary 
effect estimates and corresponding SEs from Law and 
colleagues’ meta-analysis12 of 15 colorectal cancer GWAS. 
After imputation, this meta-analysis related more than 
10 million genetic variants to colorectal cancer in people 
of European ancestry. UK BioBank data were used to 
obtain genetic instruments for age at menarche, basal 
metabolic rate, birthweight, body fat per cent age, and 
waist circumference. These data were also used in one of 
the GWAS included in Law and colleagues’ meta-
analysis,12 so, to avoid bias caused by sample overlap,13 we 
exclu ded the GWAS in which UK BioBank data were 
used and recom puted association statistics for the 
remaining 14 studies (appendix 2 table S3) with an 
inverse variance-weighted fixed-effects model similar to 
that described by Law and colleagues.12
The resulting meta-analysis population comprised 
26 397 patients with colorectal cancer and 41 481 controls. 
SNPs with poor imputa tion quality (ie, info score <0·8) 
were not inclu ded in the mendelian randomisation 
analysis. As some poten tially modifiable reproductive 
risk factors are spec ific to women, when sex-specific 
data were available we further computed colorectal 
cancer association statistics in the 7952 female cases 
and 11 680 female controls. We used MR-Base to 
harmonise SNPs to ensure that the effect estimates of 
each SNP on each trait and colorectal cancer risk 
corresponded to the same allele.11 Effect estimates for 
the association of each trait SNP with colorectal cancer 
risk are in appendix 2 (table S2). For all vitamins 
studied (ie, vitamins A, B6, B12, and E), positive 
β values mean that the effect allele was associated with 
increased serum concentrations.
Fatty acid metabolism involves sequential enzymatic 
conversions (appendix 1 p 13), and SNPs that affect the 
metabolism of one fatty acid are therefore often 
associated with circulating concentrations of several 
fatty acids.14 Additionally, many genes involved in 
desaturation and elongation of fatty acids are 
constituents of numerous fatty acid pathways, and 
thereby affects circulating concen trations of several fatty 
acid classes (appendix 1 p 13). To limit bias introduced by 
such vertical and horizontal pleiotropy, we restricted our 
analysis to classes of fatty acids (such as omega-6 
polyunsaturated fatty acids and monounsaturated fatty 
acids), rather than individual fatty acids, and excluded 
SNPs known to be associated with several fatty acid 
classes (appendix 2 table S7).
Statistical analysis
Our mendelian randomisation methods were predicated 
on the assumption that genetic variants used as instru-
ments for a risk factor are associated with the risk factor 
and not with a confounder or alternative causal pathway 
(figure 1). Additionally, to accurately estimate the size of 
the causal effect of the risk factor under investigation, 
the associations have to be linear and unaffected by 
statistical interactions.15 We used the Wald ratio to 
estimate causal effects for each SNP (appendix 1 
pp 9–12). For traits for which more than one SNP was 
available as an instrument, causal effects were estimated 
with the random-effects maximum likelihood estimation 
method.16 To assess the robustness of our findings, we 
also obtained weighted median estimates17 and mode-
based estimates.18 We used the MR-Egger regression 
approach to assess the extent to which directional 
pleiotropy could affect causal estimates.19 Finally, we did 
a leave-one-out analysis with the multiplicative random-
effects inverse variance weighted method11 to examine 
the effect of outlying and pleiotropic SNPs on causal 
estimates (appendix 2 table S4).
I² statistics were computed to estimate the proportion 
of variance across SNPs due to heterogeneity (appendix 2 
table S5). Results are reported as odds ratios per 
genetically predicted standard deviation unit increase in 
each putative risk factor (ORSD) and 95% CIs. To address 
the issue of multiple testing, we applied a Bonferroni-
corrected significance threshold, which was computed as 
0·0013 (ie, 0·05/39 [ for the 39 putative risk factors]). 
p values between 0·0013 and 0·05 were considered 
as suggestive of a potential association. The power of 
men delian randomisa tion to show a causal effect 
depends on the proportion of variance in the risk factor 
explained by the genetic variants used as instruments, 
and we therefore estimated study power at an α of 0·05 
For more on the MR-Base  see 
http://www.mrbase.org/
Figure 1: Principles of mendelian randomisation and assumptions that need to be satisfied to derive unbiased 
causal effect estimates
Dashed lines represent direct causal and potential pleiotropic effects that could violate mendelian randomisation 
assumptions. SNP=single-nucleotide polymorphism.
SNP₁
SNP2
SNPn
Modifiable 
risk  factor
Confounder
Colorectal 
cancer
Genetic variants used as instrumental
variables are associated with the risk factor
Genetic variants not associated with any 
measured or unmeasured confounders
Genetic variants affect risk only via risk factor 
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for each risk factor a priori.20 Statistical analyses were 
done in R (version 3.4.0) and mendelian randomisation 
analyses were done in MR-Base.11
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
The 39 potentially modifiable risk factors for colorectal 
cancer that we studied included 13 traits related to diet 
and lifestyle, three to fatty acid profile and metabolism, 
ten to obesity, five to lipids and lipid transport, three to 
inflammatory factors, three to sex hormones and reprod-
uction, and two to developmental and growth factors. 
The number of SNPs used as genetic instruments for 
these potentially modifiable risk factors ranged from one 
to 2487. 
With regard to the diet and lifestyle factors investigated, 
under a random-effects maxi mum likelihood estimation 
model, we noted a suggestive association between 
genetically predicted high serum vitamin B12 concen-
trations and increased risk of colorectal cancer (ORSD 1·21 
[95% CI 1·04–1·42]; p=0·016; figure 2). However, there 
was substantial heterogeneity between the SNPs used as 
instrumental variables for this association (I² 71·9). Leave-
one-out analysis showed that SNP rs602662 at a known 
risk locus for colorectal cancer had a strong influence on 
the causal estimate for serum vitamin B12 concentrations 
Figure 2: ORSD for associations between genetically predicted risk factors and colorectal cancer
We used a maximum likelihood estimate random-effects method to summarise Wald ratio estimates from individual SNPs. ORSD=odds ratio per genetically predicted 
SD unit increase in the risk factor. SNP=single-nucleotide polymorphism. *Restricted analyses that excluded SNPs associated with other classes of fatty acid. 
†ORSD estimated based on colorectal cancer summary statistics for women only.  
ORSD (95% CI)Number of SNPs
Diet and lifestyle
Alcohol consumption
Blood methionine
Blood selenium
Blood zinc
Circulating 25-hydroxyvitamin D
Circulating carotenoids
Coffee consumption
Iron status
Serum calcium
Serum vitamin A (retinol)
Serum vitamin B12
Serum vitamin B6
Serum vitamin E
Fatty acid profile and metabolism
Blood carnitine
Monounsaturated fatty acids*
Omega-6 polyunsaturated fatty acids*
Obesity
Basal metabolic rate
Birthweight
Body fat percentage
Body-mass index
Circulating adiponectin
Fasting glucose
Fasting proinsulin
HbA1c 
Waist circumference
Waist-to-hip ratio
Lipids and lipid transport
Circulating fetuin A
HDL cholesterol
LDL cholesterol
Total cholesterol
Total triglycerides
Inflammatory factors
Circulating C-reactive protein
Plasma interleukin 6 receptor subunit α
Serum IgE
Sex hormones and reproduction†
Age at menarche
Plasma oestradiol
Plasma progesterone
Developmental and growth factors
Adult height
Plasma IGF-I
3
1
1
2
5
1
4
3
8
2
9
1
3
18
1
6
693  
93
370
964
10
23
8
11
319
35
1
58
44
28
34
14
1
3
151
1
2
2487
1
 1·60 (0·85−3·04)
 0·92 (0·70−1·19)
 0·85 (0·75−0·96)
 0·94 (0·86−1·03)
 0·99 (0·90−1·09)
 1·04 (0·94−1·15)
 1·17 (0·88−1·55)
 1·17 (1·00−1·36)
 0·93 (0·83−1·05)
 1·07 (0·78−1·47)
 1·21 (1·04−1·42)
 1·04 (0·90−1·20)
 0·94 (0·76−1·17)
 0·99 (0·92−1·06)
 1·07 (0·78−1·46)
 1·15 (0·98−1·36)
 1·10 (1·03−1·18)
 1·10 (0·92−1·31)
 1·14 (1·03−1·25)
 1·09 (1·01−1·17)
 0·93 (0·81−1·07)
 1·04 (0·92−1·18)
 0·97 (0·90−1·03)
 1·02 (0·85−1·22)
 1·13 (1·02−1·26)
 1·07 (0·91−1·27)
 0·98 (0·94−1·02)
 1·03 (0·92−1·14)
 1·14 (1·04−1·25)
 1·09 (1·01−1·18)
 0·93 (0·84−1·04)
 0·95 (0·83−1·10)
 0·98 (0·96−1·00)
 0·92 (0·82−1·03)
 0·99 (0·84−1·18)
 1·27 (0·53−3·02)
 0·90 (0·76−1·07)
 1·04 (1·00−1·08)
 0·88 (0·76−1·01)
p value
0·15
0·51
0·0078
0·18
0·89
0·45
0·27
0·049
0·26
0·66
0·016
0·59
0·60
0·68
0·67
0·095
0·0079
0·31
0·0086
0·023
0·31
0·52
0·31
0·87
0·018
0·41
0·37
0·62
0·0056
0·025
0·19
0·53
0·035
0·16
0·92
0·59
0·24
0·032
0·064
I²
 60·0
 ··
 ··
 0·0
 0·0
 ··
 20·9
 0·0
 18·8
 59·4
 71·9
 ··
 0·0
 
53·4
 ··
 53·1
 
46·7
 57·9
 37·1
 31·1
 0·0
 48·8
 0·0
 51·7
 38·0
 41·5
 ··
 53·5
 53·4
 32·2
 51·5
 56·5
 ··
 0·0
 20·4
 ··
 0·0
 
39·4
 ··
0·8 1·6 1·81·41·21·0
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PubMed identifier SNPs used in 
mendelian 
randomisation 
analysis
Proportion of 
variance 
explained by 
SNPs
Power to 
identify ORSD 
of 0·91 or 1·10
Power to 
identify ORSD 
of 0·75 or 1·33
F statistic
Diet and lifestyle
Alcohol consumption 28 937 693 3 0·002 0·082 0·364 66·73
Blood methionine 24 816 252 1 0·004 0·124 0·676 30·57
Blood selenium 23 720 494 1 0·020 0·417 1·000 114·36
Blood zinc 23 720 494 2 0·046 0·746 1·000 62·58
Circulating 25-hydroxyvitamin D 29 343 764 5 0·026 0·512 1·000 431·37
Circulating carotenoids 19 185 284 1 0·028 0·531 1·000 106·36
Coffee consumption 25 288 136 4 0·005 0·147 0·788 124·16
Iron status 25 352 340 3 0·012 0·260 0·981 190·40
Serum calcium 24 068 962 8 0·026 0·503 1·000 202·32
Serum vitamin A (retinol) 21 878 437 2 0·007 0·175 0·879 34·69
Serum vitamin B12 23 754 956 9 0·047 0·760 1·000 252·08
Serum vitamin B6 19 303 062 1 0·014 0·307 0·994 26·67
Serum vitamin E 21 729 881 3 0·007 0·167 0·857 10·92
Fatty acid profile and metabolism
Blood carnitine 24 816 252 18 0·139 0·995 1·000 65·81
Monounsaturated fatty acids* 27 005 778 1 0·003 0·097 0·493 36·29
Omega-6 polyunsaturated fatty acids* 27 005 778 6 0·024 0·477 1·000 55·68
Obesity
Basal metabolic rate 30 305 743 693 0·122 0·990 1·000 66·11
Birthweight 30 305 743 93 0·025 0·487 1·000 52·72
Body fat percentage 30 305 743 370 0·053 0·806 1·000 50·28
Body-mass index 30 124 842 964 0·079 0·929 1·000 60·69
Circulating adiponectin 22 479 202 10 0·018 0·372 0·999 65·12
Fasting glucose 22 581 228 23 0·036 0·639 1·000 93·73
Fasting proinsulin 20 081 858 8 0·061 0·858 1·000 87·33
Glycated haemoglobin A1c 20 858 683 11 0·018 0·381 0·999 78·72
Waist circumference 30 305 743 319 0·047 0·754 1·000 51·68
Waist-to-hip ratio 25 673 412 35 0·018 0·369 0·999 57·66
Lipids and lipid transport
Circulating fetuin-A 28 379 451 1 0·143 0·996 1·000 1331·92
HDL cholesterol 24 097 068 58 0·061 0·856 1·000 105·31
LDL cholesterol 24 097 068 44 0·079 0·930 1·000 182·74
Total cholesterol 27 005 778 28 0·095 0·964 1·000 80·05
Total triglycerides 24 097 068 34 0·061 0·857 1·000 180·23
Inflammatory factors
Circulating C-reactive protein 21 300 955 14 0·036 0·640 1·000 220·09
Plasma interleukin-6 receptor subunit α 29 875 488 1 0·604 1·000 1·000 5038·85
Serum immunoglobulin E 22 075 330 3 0·016 0·342 0·997 79·70
Sex hormones and reproduction†
Age at menarche 30 305 743 151 0·048 0·303 0·993 58·11
Plasma oestradiol 26 014 426 1 0·011 0·105 0·553 31·47
Plasma progesterone 26 014 426 2 0·035 0·235 0·965 52·44
Developmental and growth factors
Adult height 30 124 842 2487 0·380 1·000 1·000 171·41
Plasma IGF-I 29 875 488 1 0·014 0·314 0·995 48·51
The F statistic was used as a measure of potential weak instrument bias, with a low statistic (ie, <10) indicative of possible bias. SNPs=single-nucleotide polymorphisms. 
ORSD=odds ratio per genetically predicted SD unit increase in risk factor. *Restricted analyses that excluded SNPs associated with other classes of fatty acids. †ORSD estimated 
based on colorectal cancer summary statistics for women only.
Table: Modifiable risk factors for colorectal cancer included in mendelian randomisation analysis
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(appendix 2 table S4).12 There was a suggestive associ-
ation between genetic ally predicted increased serum iron 
concentrations and increased risk of colorectal cancer 
(ORSD 1·17 [95% CI 1·00–1·36]; p=0·049), with no outlying 
genetic variant identified (appendix 1 pp 9–12). We also 
noted a suggestive association between raised serum 
selenium concentrations and decreased colorectal cancer 
risk (ORSD 0·85 [95% CI 0·75–0·96]; p=0·0078), but this 
association was based on only one SNP. Genetically 
predicted alcohol and coffee consumption, and blood 
concentrations of methionine, zinc, 25-hydroxyvitamin D, 
carotenoids, calcium, and vitamins A, B6, and E were not 
associated with risk of colorectal cancer (figure 2). Causal 
effect estimates for serum vitamin B12 concentration were 
similar in sens itivity analyses in which we used weighted 
median and mode-based methods (appendix 2 table S5). 
MR-Egger regression showed no evi dence of directional 
pleiotropy in the analyses of vita min B12 or serum iron 
concentration (appendix 2 table S6). The causal effects 
estimated by MR-Egger were not significant for vitamin B12 
(appendix 2 table S5).
In our restricted analysis of fatty acid profile and 
metabolism, no association was noted between risk of 
colorectal cancer and omega-6 polyunsaturated or mono-
unsaturated fatty acids concentrations or blood concen-
trations of the fatty acid transport molecule carnitine 
(figure 2). After removal of potentially pleiotropic SNPs, 
only one SNP was suitable for use as an instrumental 
variable for monounsaturated fatty acids concentration, 
which meant that sensitivity analysis could not be done.
When we included information about all genetic vari-
ants associated with cardiometabolic factors, meas ures of 
obesity and hyperlipidaemia were suggest ively associated 
with colorectal cancer (figure 2). Specifically, suggestive 
associ ations were noted between genetically predicted 
basal metabolic rate (ORSD 1·10 [95% CI 1·03–1·18]; 
p=0·0079), body fat percentage (1·14 [1·03–1·25]; 
p=0·0086), BMI (1·09 [1·01–1·17]; p=0·023) and waist 
circumference (1·13 [1·02–1·26]; p=0·018) and increased 
risk of colorectal cancer. We noted no association between 
birthweight or circulating adiponectin concentrations and 
risk of colorectal cancer (figure 2). Causal estimates for 
basal metabolic rate, BMI, and waist circumference were 
broadly concordant in weighted median and mode-based 
sensitivity analyses (appendix 2 table S5). Conversely, the 
effect estimate for body fat percentage from the mode-
based estimate approach was not significantly associated 
with colorectal cancer risk (appendix 2 table S5), 
suggesting that some of the instruments used to assess 
the causal effects of body fat percent age might have been 
invalid. MR-Egger regression did not identify evi dence of 
horizontal pleiotropy for body fat percentage or any other 
obesity-related trait (appendix 2 table S6).
Genetically predicted LDL cholesterol (ORSD 1·14 
[95% CI 1·04–1·25]; p=0·0056) and total cholesterol 
(1·09 [1·01–1·18]; p=0·025) were suggestively associated 
with increased risk of colorectal cancer. No association 
between HDL cholesterol or total triglyceride concentra-
tions and colorectal cancer risk was detected (figure 2). 
Similarly, genetically predicted metrics of glycaemia were 
not associated with colorectal cancer risk (figure 2).
A suggestive association based on one SNP was noted 
between plasma concentrations of interleukin 6 recep-
tor subunit α and decreased risk of colorectal cancer 
(ORSD 0·98 [95% CI 0·96–1·00]; p=0·035). Associations 
between circulating C-reactive protein and serum IgE 
and colorectal cancer risk were not identified (figure 2).
We noted no association between age at menarche, a 
surrogate for endogenous oestrogen expos ure, and risk of 
colorectal cancer (ORSD 0·99 [95% CI 0·84–1·18]; p=0·92) 
in women. Similarly, we did not note associations between 
plasma oestradiol and progesterone concentrations and 
colorectal cancer (figure 2). The genetic variants used as 
instruments for these traits explain only a small proportion 
of their variance (table), and we were therefore unable to 
exclude a small-to-moderate effect of sex hormone 
exposure on colorectal cancer risk. MR-Egger regression 
analysis of genetic instruments for age at menopause 
provided evidence of horizontal pleiotropy (p=0·01; 
appendix 2 table S6) and we therefore did not consider this 
trait in our men delian randomisation analysis.
Although height is not modifiable once stabilised in 
adulthood, it is affected by developmental factors and 
growth processes, which might be modifiable. In con-
cordance with evidence reviewed by the World Cancer 
Research Fund and the American Institute for Cancer 
Research,3 we noted a suggestive association between 
genetically predicted adult height and increased odds of 
colorectal cancer (ORSD 1·04 [95% CI 1·00–1·08]; p=0·032), 
further supporting the notion that childhood factors affect 
subsequent disease risk. We noted no association between 
plasma IGF-1 concentrations and risk of colorectal cancer 
(figure 2). However, this analysis was based on only one 
genetic variant that accounts for only a small proportion of 
IGF-1 variance, and therefore had little power to detect an 
effect (table). 
F statistics were high (>10) for all considered traits 
(table), but some of our findings might have been affected 
by weak instrument bias. For 19 of the traits that were not 
associated with colorectal cancer risk, our study had less 
than 80% power to identify ORSD less than 0·91 or >1·10 
(table), and we therefore cannot exclude the possibility that 
these traits have a small effect on disease risk.
Discussion
This mendelian randomisation study, in which we used 
genetic variants as proxies for putative risk factors, 
provides suggestive evidence for associations between 
increased body fat percentage, BMI, waist circumference, 
basal metabolic rate, adult height, serum vitamin B12 
concentrations, serum iron concentrations, LDL choles-
terol, and total cholesterol and increased colorectal cancer 
risk. There was also suggestive evidence for possible 
associations between serum selenium and interleukin 6 
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receptor subunit α concentrations and decreased colo-
rectal cancer risk.
Strengths of this study include that we examined 
multiple factors in relation to colorectal cancer risk by 
exploiting data from large GWAS. Many of the putative 
risk factors considered in this study have not previously 
been assessed with mendelian randomisation frameworks 
(appendix 2 table S8). Of the factors for which suggestive 
associations were identified, body fat percentage, waist 
circumference, basal metabolic rate, iron status, and blood 
selenium, serum vitamin B12, and plasma interleukin 6 
subunit α concentrations have not previously been 
included in mendelian randomisation analyses of colo-
rectal cancer risk. Even for risk factors that were included 
in previous analyses,21 the number of cases and controls in 
our analysis affords us greater power to detect causal 
associations with colorectal cancer and allows us to 
more accurately estimate effect magnitudes. For example, 
whereas Rodriguez-Broadbent and colleagues22 did not 
identify a significant association between LDL chol-
esterol and risk of colorectal cancer (ORSD 1·05 [95% CI 
0·92–1·18]; p=0·49), we identified a suggestive rela-
tionship (1·14 [1·04–1·25]; p=0·0056), possibly because 
our study had increased power. By comparing the results 
of this study to those of previous mendelian randomisation 
analyses of colorectal cancer risk, we could also identify 
previously reported causal relationships that might be false 
positives—eg, the previously reported association between 
genetically predicted C-reactive protein con centrations and 
colorectal cancer risk.23
As with all mendelian randomisation studies, excluding 
pleiotropy or an alternative direct causal pathway as the 
basis of the association was a challenge. High I² statistics 
for many traits suggest that pleiotropy was present in this 
analysis. To address this issue, we did sensitivity analyses 
with the weighted median and model-based estimate 
methods, which can provide unbiased causal effect 
estimates even when many of the genetic variants used 
represent invalid instruments.17,18 For most of the traits 
with either a significant or suggestive association with 
colorectal cancer risk, the effects estimated were similar in 
our sensitivity analyses, supporting causal relationships. 
Differences in causal effect estimates from the random-
effects maximum likelihood estimation model and 
MR-Egger regression are possibly a result of the reduced 
power of MR-Egger regression to detect causal effects.19 
Importantly, there is overlap between the cases and 
controls in this study, and those included in previous 
mendelian randomisation analyses,21 and results from this 
study cannot therefore be considered to be independent 
replication.
We found no evidence for an association between 
genetically predicted fasting glucose and proinsulin and 
risk of colorectal cancer, suggesting that metabolic synd-
rome might not influence risk through these factors. 
However, because of the limited power of this analysis, we 
cannot preclude these factors having small effects on 
colorectal cancer risk. Our estimate that an increase in 
adult height of one SD increases colorectal cancer risk by 
4% is concordant with the findings of many observational 
studies.3 Increased exposure to growth hormones and 
insulin-like growth factors during child hood have been 
posited as potential mechanisms for this association.24 
Although we did not identify a significant association 
between plasma IGF-1 concentrations and colorectal 
cancer risk, the limited power of this analysis means that 
we cannot rule out small-to-moderate effect sizes. Taller 
adults tend to have larger colons than do shorter adults, 
and thus larger populations of at-risk cells might also 
explain the apparent causal inference.
Our findings of an association between genetic-
ally predicted vitamin B12 concentrations and colorectal 
cancer risk are concordant with those of a random-
ised trial25 in which vitamin B12 supplementation was 
associated with increased risk. Although the associations 
were weaker than that for vitamin B12, we also found 
suggestive evidence to support high selenium concen-
trations having a beneficial effect and high iron 
concentrations a detrimental effect.
Further research is required to decipher the biological 
pathways underpinning associations. However, irres-
pective of the exact functional basis of associations identi-
fied via a genetic approach, our analysis highlights 
important targets for primary prevention of colorectal 
cancer in the population. First, the suggestive association 
between obesity and colorectal cancer risk suggests that 
reducing the population incidence of obesity is a priority 
for cancer prevention. Second, our findings suggest that 
hypercholesterolemia is causally linked to colorectal cancer 
risk and therefore support the hypothesis that increasing 
use of statins for prevention of cardiovascular disease 
could also reduce the burden of colorectal cancer. The 
limited power of this study to robustly define the rela-
ionship between some putative risk factors and colorectal 
cancer provides the impetus for larger mendelian 
randomisa tion studies, which could elucidate relationships 
for the spectrum of colorectal neoplasia. Such work could 
shed additional light on other potentially modifiable 
factors that could then be targeted to reduce the overall 
burden of colorectal cancer.
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